Death receptor 3 (DR3) is a typical member of the tumor necrosis factor receptor family, and was initially identified as a T-cell co-stimulatory molecule. However, further studies revealed a more complex and partly dichotomous role for DR3 and its ligand TL1A under (patho)physiological conditions. TL1A and DR3 are not only a driving force in the development of autoimmune and inflammatory diseases, but also play an important role in counteracting these processes through an increase in the number of regulatory T cells. Ligands of the tumor necrosis factor family typically occur in two forms, membrane-bound and soluble, that can differ strikingly with respect to their efficacy in activating their corresponding receptor(s). Ligand-based approaches to activate the TL1A-DR3 pathway therefore require understanding of the molecular prerequisites of TL1A-based DR3 activation. To date, this has not been addressed. Here, we show that recombinant soluble trimeric TL1A is fully sufficient to strongly activate DR3-associated pro-and anti-apoptotic signaling pathways. In contrast to the TRAIL death receptors, which are much better activated by soluble TRAIL upon secondary ligand oligomerization, but similarly to the death receptor tumor necrosis factor receptor 1, DR3 is efficiently activated by soluble TL1A trimers. Additionally, we have measured the affinity of TL1A-DR3 interaction in a cell-based system, and demonstrated TL1A-induced DR3 internalization. Identification of DR3 as a tumor necrosis factor receptor that responds to soluble ligand trimers without further oligomerization provides a basis for therapeutic exploitation of the TL1A-DR3 pathway.
Introduction
Death receptor 3 (DR3, also known as TNFRSF25, Wsl-1, TRAMP and APO-3) and its ligand TL1A (TNFSF15) are typical members of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and the TNF ligand superfamily (TNFSF). DR3 belongs to the death receptor sub-group of the TNFRSF [1] , and its highest degree of sequence similarity is with TNF receptor 1 (TNFR1). Binding of TL1A to DR3 induces recruitment of adapter proteins such as TNFR-associated death domain (TRADD), Fas-associated death domain (FADD) and TNFR-associated factor 2 (TRAF2) to the cytoplasmic tail of the receptor. Association of caspase-8 with FADD allows stepwise activation of the former, and initiates a cascade of proteolytic cleavage events that culminate in caspase-3 activation and trigger the execution phase of apoptosis [2] . Additionally, DR3 is capable of activating the pro-inflammatory and anti-apoptotic classical nuclear factor jB (NFjB) pathway via receptor interacting protein 1 (RIP1) [3] .
TL1A and DR3 were initially identified as T-cell co-stimulatory molecules [4] , but animal models suggest a more complex, partly dichotomous role for the TL1A-DR3 system in T-cell immunity. On the one hand, the TL1A-DR3 system has been recognized as a driving force in development of autoimmune and inflammatory diseases such as asthma, inflammatory bowel disease, rheumatoid arthritis and psoriasis [4] . On the other hand, DR3-mediated in vivo expansion of regulatory T cells prevented allergic lung inflammation, promoted cardiac allograft survival, and reduced graft-versus-host disease [5] [6] [7] . Increasing the frequency of regulatory T cells through, DR3 activation may also be exploited therapeutically.
To date, attempts to activate DR3 have mainly focused on receptor-specific agonistic antibodies [5] [6] [7] . Therapeutically, this approach may be limited by Fcc receptor-dependent effector activities such as antibodydependent cellular cytotoxicity, but also by the requirement of many anti-TNFRSF antibodies for Fcc receptor binding to unleash their full agonistic potential [8] . Antibody variants with reduced or abrogated binding to the Fcc receptor are available, but this may reduce their agonistic activity, as recently shown for antibodies targeting the TNFRSF receptors CD40, DR5 and Fn14 [8] . Ligand-based therapeutic approaches constitute an interesting alternative, but their rational design critically depends on defining the molecular prerequisites for ligand-mediated receptor activation.
TNFSF ligands are single membrane-spanning proteins with a characteristic extracellular C-terminal TNF homology domain. The TNF homology domain is essential for receptor binding and self-assembly to form homo-trimeric ligands. Most TNFSF ligands also occur as soluble molecules, generated either through proteolytic cleavage or by alternative splicing. Soluble TNFSF ligands typically also form trimers, as they contain the TNF homology domain. Importantly, TNFRSF receptors may differ in their ability to respond to the membrane-bound and soluble forms of their ligands. For example, soluble TNF binds to TNFR1 and TNFR2, but only activates TNFR1 efficiently. In contrast, membrane-bound TNF binds to and activates both TNFR1 and TNFR2 [9] . Other examples of TNFRSF receptors that depend on the membrane-bound ligand for full-blown activation include CD95, TRAILR2, CD27, 41BB, TACI and OX40 [10] [11] [12] [13] . Notably, secondary oligomerization of the soluble ligands targeting these TNFRSF receptors increases specific activity by several orders of magnitude, thereby generating highly active agonists [10] .
Despite the therapeutic potential of the TL1A-DR3 system, the effects of oligomerization on the ability of soluble TL1A to activate DR3 have not yet been addressed. Here, we report that soluble TL1A is fully sufficient to strongly stimulate DR3. Additionally, we characterized the TL1A-DR3 interaction in a cellbased system, and provide evidence for ligand-induced DR3 internalization.
Results

Production and biochemical characterization of soluble TL1A
To study TL1A-mediated DR3 activation, we generated a Flag-tagged TL1A variant (Fig. 1A, top panel) consisting of the TNF homology domain of human TL1A with an N-terminal Flag tag and the chicken tenascin C (TNC) domain. The Flag tag allows affinity purification and antibody-mediated secondary oligomerization. The TNC domain stabilizes the trimeric structure of TNFSF ligands through strong non-covalent interactions and disulfide bonding [14] . As previously shown for CD27L [13] , trimer instability may reduce ligand activity irrespective of the oligomerization status, and this possibility therefore had to be excluded. Flag-TNC-TL1A was expressed in HEK293T cells, reaching concentrations of 4-10 lgÁmL À1 in the supernatant. Silver staining and Western blot analysis (Fig. 1A , lower panel) revealed that the vast majority of affinity-purified Flag-TNC-TL1A migrated in non-reducing SDS/PAGE at a position corresponding to the molecular weight of a trimer. Only a small fraction of Flag-TNC-TL1A migrated at positions corresponding to a lower molecular weight. Under reducing conditions, there was one dominant band of approximately 28 kDa and two somewhat faster-migrating bands, suggesting glycosylation of TL1A, similar to other TNFSF ligands.
Soluble TL1A, like soluble TNF, induces cell death and NFjB activation DR3 and its close relative TNFR1 trigger apoptotic as well as non-apoptotic signaling pathways [2] .
Interestingly, in DR3-and TNFR1-positive erythroleukemic TF-1 cells (Fig. 1B) , a soluble TNFR1-specific TNF mutant [Flag-TNF(32W/86T)] [15] induced significantly higher levels of expression of the NFjB target gene encoding interleukin 8 (IL8) compared to Flag-TNC-TL1A (Fig. 1C) . A confounding effect due to concomitant TNFR2 activation was excluded due to use of the TNFR1-specific TNF variant. Flag-TNC-TL1A and TNF furthermore induced cell death (Fig. 1D ) and caspase-3 activation (Fig. 1E) ).
TL1A-induced cytotoxicity is independent of autocrine TNF secretion
The moderate cytotoxic effect of Flag-TNC-TL1A was reminiscent of that of TNF-like weak inducer of apoptosis (TWEAK), another TNFSF ligand. Binding of TWEAK to its receptor Fn14 triggers cell death in some cell lines. However, rather than relying on direct activation of pro-apoptotic adapter proteins and caspases as in the case of TNFR1 or the TRAIL death receptors, TWEAK utilizes NFjB-dependent induction of TNF to exert cytotoxicity in an autocrine manner via TNFR1 [16] . We therefore wished to determine whether the modest cytotoxic effects observed upon TL1A treatment were directly triggered by DR3-associated death pathways or were due to DR3-mediated NFjB activation with subsequent TNF secretion. In line with the data shown in Fig. 1C , Flag-TNC-TL1A induced phosphorylation of inhibitor of jBa (IjBa), a surrogate marker for ongoing NFjB activation ( Fig. 2A) . Pre-treatment with the TNF-neutralizing TNFR2-Fc fusion protein etanercept did not negatively affect Flag-TNC-TL1A-induced IjBa phosphorylation ( Fig. 2A) , but, as expected, rescued TF-1 cells from TNF-induced cell death (Fig. 2B ). Flag-TNC-TL1A-mediated cytotoxicity remained unaffected in the presence of etanercept (Fig. 2C) . Together, these results suggest that TL1A-induced cell death is directly mediated through DR3.
Oligomerization of TL1A does not enhance the efficacy of DR3 activation ). Caspase activation was blocked by addition of zVAD-fmk (100 lM) 1 h before TRAIL stimulation. After 6 h, supernatants were collected and IL8 production was analyzed using ELISA. Values are means AE SEM from three experiments.
Secondary oligomerization of Flag-TNC-TL1A using an anti-Flag antibody (clone M2) did not significantly affect TL1A-induced loss of viability (Fig. 3A) . Similar observations were obtained using a hexameric Fc-TL1A fusion protein (Fig. 3B,C) . In sharp contrast, but as expected, anti-Flag antibody-mediated oligomerization of a Flag-tagged TRAIL variant drastically increased the ability of this soluble TNFSF ligand to induce cell death (Fig. 3D ). This excludes the possibility of inefficient cross-linking as a cause for poor Flag-TNC-TL1A-mediated killing.
In line with these findings, co-immunoprecipitation of trimeric Flag-TNC-TL1A demonstrated ligandinduced association of DR3 with TRAF2, inhibitor of apoptosis protein 2 (cIAP2) and RIP1 (Fig. 3E ). Flag-TNC-TL1A treatment resulted in slower-migrating, potentially ubiquitinated, RIP1, indicative of an IjB kinase-stimulating, DR3-associated signaling complex. Indeed, Flag-TNC-TL1A stimulation resulted in biphasic IjBa phosphorylation, which was slightly more pronounced after challenge with oligomerized Flag-TNC-TL1A+M2 (Fig. 3F) . Consistently, TL1A-induced IL8 secretion was somewhat higher in Flag-TNC-TL1A+M2-treated cells (Fig. 3G) . However, the oligomerization-mediated enhancement of specific Flag-TNC-TL1A activity was marginal when compared to the corresponding effect observed with Flag-TRAIL (Fig. 3H) . In TF-1 cells protected from apoptosis with the pan-caspase inhibitor zVAD-fmk, anti-Flag monoclonal antibody-oligomerized Flag-TRAIL acted as a potent IL8 inductor, whereas even high doses of trimeric Flag-TRAIL failed to effectively induce IL8 secretion. In summary, oligomerization had no major effect on the ability of soluble TL1A to activate proand anti-apoptotic DR3 signaling pathways.
Binding studies of TL1A to DR3
Affinity of a ligand for its corresponding receptor(s) is a major determinant of ligand-induced receptor activation. To date, the biophysical properties of the TL1A-DR3 interaction have been poorly characterized. We generated a highly traceable TL1A probe by fusing Flag-TNC-TL1A to the C-terminus of Gaussia princeps luciferase (GpL) yielding GpL-Flag-TNC-TL1A (Fig. 4A, top panel) . Similar to Flag-TNC-TL1A, the majority of affinity-purified GpL-Flag-TNC-TL1A migrated in non-reducing SDS/PAGE at a position corresponding to the molecular weight of a trimer (Fig. 4A, lower panel) . Importantly, the GpL domain in the GpL-Flag-TNC-TL1A fusion protein did not impede the activity of the TL1A domain, as Flag-TNC-TL1A and GpL-Flag-TNC-TL1A were comparably effective with regard to cell death induction (Fig. 4B) . After substrate addition, light emission increased linearly with the GpL-Flag-TNC-TL1A concentration (Fig. 4C ). As expected, binding of the GpLtagged TL1A construct to DR3-positive TF-1 cells was competed by Flag-TNC-TL1A (Fig. 4D) . Increasing the ratio of Flag-TNC-TL1A to GpL-Flag-TNC-TL1A linearly correlated with reduced light emission, reflecting competition of both ligands for DR3 binding. Following functional characterization of the GpLFlag-TNC-TL1A construct, we next investigated the receptor affinity of TL1A for DR3 by measuring the equilibrium dissociation constant (K D ) in equilibrium binding studies. For this purpose, we generated a HeLa cell line showing doxycycline-inducible expression of a DR3 construct lacking the death domain (HeLa-DR3DDD). The death domain deletion in DR3 was made to avoid previously reported cytotoxic effects due to DR3 over-expression [2] . Flow cytometry revealed significant doxycycline-mediated induction of DR3 expression in HeLa-DR3DDD cells (Fig. 4E) , which was completely lacking in the absence of doxycycline (data not shown). Addition of doxycycline increased binding of GpL-Flag-TNC-TL1A to HeLa-DR3DDD cells approximately 300-fold compared with untreated controls (Fig. 4F) . Determination of nonspecific ligand binding was achieved by analyzing binding of GpL-Flag-TNC-TL1A to HeLa-DR3DDD cells in the absence of doxycycline. To determine total binding, we used doxycycline-treated, and thus DR3DDD-expressing, cells, and GpL-Flag-TNC-TL1A concentrations ranging from 14.7 to 7350 pM. The specific binding data obtained (difference between total and non-specific binding) fitted with high significance to one-site binding curves, and revealed a K D value of 3777 AE 2745 pM for GpL-Flag-TNC-TL1A in HeLa-DR3DDD cells (Fig. 4G ).
TL1A binding to DR3 triggers receptor internalization
Ligand-activated death receptors depend to a varying degree on internalization to ignite specific cellular pathways [17] . For the TL1A-DR3 system, trafficking events such as receptor internalization have not yet been investigated. We therefore determined whether association of TL1A with DR3 changes the plasma membrane distribution of the latter. By targeting the Flag tag of the Flag-TNC-TL1A construct using a primary anti-Flag antibody and a fluorophore-conjugated secondary antibody, we were able to trace the distribution of TL1A by fluorescence microscopy.
Staining of doxycycline-treated HeLa-DR3DDD cells loaded on ice with Flag-TNC-TL1A (ligand is shown in red) generated a fluorescent pattern with pronounced intensity at the plasma membrane (Fig. 5A) . Interestingly, the distribution of TL1A changed drastically at 37°C (Fig. 5B) . Fluorescence signals were now barely detectable at the plasma membrane, but accumulated in the cytoplasm. To exclude unspecific staining, HeLa-DR3DDD cells without doxycycline treatment, and thus without DR3 expression, were analyzed using the same staining procedure (Fig. 5C ). As expected, no TL1A-derived fluorescence signal was detectable. Essentially similar results were obtained when DR3DDD-expressing cells were stimulated with anti-Flag monoclonal antibody-oligomerized Flag-TNC-TL1A (Fig. 5D-F) , confirming our previous results that indicated comparable activity of soluble , incubation for 18 h). Subsequently, cells were challenged with the indicated concentrations of GpLFlag-TNC-TL1A (1 h, 37°C). After 10 washes with ice-cold PBS to remove unbound ligand, cells were harvested and transferred into 50 lL medium to determine cell-associated luciferase activity. Non-specific binding was determined from the samples without doxycycline, as these cells lack DR3 expression. Total binding was determined in doxycycline-treated HeLa-DR3DDD cells challenged with GpL-FLAG-TNC-TL1A. To calculate specific binding, non-specific binding was subtracted from the corresponding total binding values. Values for the maximum of specifically bound GpL activity (B max ) and the dissociation constant (K D ) were calculated using GRAPHPAD PRISM5 software by nonlinear regression analysis (one site specific binding model). The results for one representative experiment of three performed are shown.
trimeric and secondary oligomerized TL1A. Admittedly, the observed translocation of DR3DDD into the cytoplasm upon shifting cells from 4°C to 37°C may merely reflect physiological turnover processes of the plasma membrane rather than TL1A-induced receptor trafficking events. We therefore generated another 
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HeLa cell line showing doxycycline-inducible expression of a DR3 construct completely lacking all cytoplasmic residues (HeLa-DR3Dcyt, deletion of amino acids 222-321). Doxycycline treatment induced robust expression of this DR3 variant, again with dominant plasma membrane localization (Fig. 5G) . However, in these cells, the TL1A-derived fluorescence signals persisted predominantly at the plasma membrane even upon shifting the temperature to 37°C (Fig. 5H ). This indicates disturbed DR3 trafficking due to the loss of cytoplasmic residues. TL1A-induced DR3 internalization was also detectable by flow cytometry. Upon TL1A treatment, we observed a significant loss of DR3 from the surface of TF-1 cells (Fig. 5J ) in a timedependent manner (Fig. 5K) .
SMAC mimetics boost DR3-mediated cell death induction
We have demonstrated that DR3 signaling, like TNFR1 signaling, is predominantly pro-inflammatory. In TNFR1 signaling, small molecules mimicking properties of the pro-apoptotic protein second mitochondria-derived activator of caspase (SMAC) are capable of shifting the cellular response from inflammation to cell death induction [18] . In the TL1A-DR3 system, this potentially therapeutically exploitable phenomenon has not yet been addressed. We consequently pre-treated TF-1 cells with the SMAC mimetics BV6 (Fig. 6A) and LCL161 (Fig. 6B) . Soluble trimeric Flag-TNC-TL1A alone displayed only marginal cytotoxicity (green bars), whereas combinatorial treatment with Flag-TNC-TL1A and SMAC mimetics resulted in a drastic loss of viability (black bars). These results also highlight the fact that trimeric soluble Flag-TNC-TL1A is sufficient for DR3 activation.
Discussion
Surprisingly little is known about the fundamental mechanisms that underlie DR3 activation by TL1A, although the TL1A-DR3 system has been heavily investigated as a therapeutic target in human diseases, mainly based on data from mouse models of immune pathologies [5] [6] [7] . Notably murine and human DR3 differ in structure, isoform expression and tissue distribution [19] , which highlights the importance of our effort to characterize the human TL1A-DR3 interaction. Additionally, many mouse models used agonistic DR3 antibodies rather than the natural ligand TL1A [5] [6] [7] . However, antibody-mediated TNFRSF receptor activation does not necessarily reflect ligand-induced activation, and may even trigger a fundamentally different cellular response, as demonstrated for CD95 and Fn14 [20, 21] . Binding of anti-TNFRSF receptor antibodies to Fcc receptors may enhance their agonistic potential, but may also trigger effector activities such as antibodydependent cellular cytotoxicity. TL1A-based DR3 activation may be a promising alternative to antibodymediated DR3 activation, but requires understanding of the molecular prerequisites, as TNFRSF receptors can differ tremendously in their capacity to respond to soluble TNFSF ligands.
Indeed, soluble TNF was strikingly more effective than soluble TL1A with regard to cell death induction; the LD 50 for TNF was 0.54 ngÁmL À1 , compared with 1740 ngÁmL À1 for TL1A. This difference in LD 50 of almost four orders of magnitude is astonishing, given that the receptor signaling complexes and downstream signaling pathways of TNFR1 and DR3 appear to be largely overlapping [22] . Interestingly, TNFR1 and DR3 signaling involve cIAP1-TRAF2 complexes [22] . Depletion or degradation of cIAP1-TRAF2 complexes, as has been demonstrated in response to TWEAK-induced activation of Fn14, allows stabilization of NFjB-inducing kinase with subsequent activation of the non-canonical NFjB pathway. Subsequent secretion of the NFjB target gene TNF finally induces apoptotic cell death in an autocrine manner via TNFR1 [16, 23, 24] . However, the modest pro-apoptotic effect of DR3 is unlikely to be triggered by cIAP1-TRAF2 depletion and autocrine TNF secretion, as the TNF-blocking agent etanercept failed to rescue TL1A-treated cells, but conferred protection against exogenous TNF administration (Fig. 2) . The striking differences in the LD 50 values for TNF and TL1A may therefore reflect differences in the inherent strength of receptor activation between soluble and membrane-bound (or artificially oligomerized) TL1A [10] , comparable to those observed with oligomerized and non-oligomerized Flag-TRAIL (Fig. 3D,H) . We clearly demonstrated that soluble trimeric TL1A is sufficient to induce a functional DR3 signaling complex (Fig. 3E) and to activate pro-and anti-apoptotic pathways (Fig. 3A,G) . Further oligomerization of trimeric Flag-TNC-TL1A did not significantly enhance DR3 signaling (Fig. 3A,C) . Previous studies reported secretion of interferon c from human CD4 + T cells upon stimulation with soluble TL1A and in co-culture assays with TL1A-positive cells [25, 26] . Additionally, binding of soluble hexameric Fc fusion proteins of murine and human TL1A to DR3 has been demonstrated [27] , and Fc-TL1A triggered proliferation of DR3-positive murine Th17 cells [28] . However, potential differences in the specific activity of membrane-bound versus soluble TL1A or trimeric versus more highly oligomerized TL1A have not been addressed in these studies. It is noteworthy that side-by-side comparison of a murine hexameric Fc-TL1A fusion protein and an agonistic antibody indicated a higher capacity of the former to induce proliferation of regulatory T cells and caspase activation [29] . Hence, the higher activity of Fc-TL1A may be attributable to differences in the effectiveness of ligand-based versus antibody-mediated DR3 activation, and may not be related to TL1A oligomerization, again illustrating the importance of elucidating mechanistic aspects of DR3 activation.
To elicit a cellular response, ligand binding to surface receptors is a prerequisite, and depends on the affinity of the ligand for the receptor. Biophysically, the TL1A-DR3 interaction has been poorly characterized to date. Cellular binding studies involving chemically labeled TNF ligands (e.g. iodinated or biotinylated ligands) have limitations, such as high batch-to-batch variations in labeling efficacy and generation of mixtures of molecules with non-homogeneous activity. We circumvented this by using a GpLFlag-TNC-TL1A construct (Fig. 4A) . This allowed assessment of the equilibrium dissociation constant (K D ) in intact human cells. The K D of the TL1A-DR3 interaction in HeLa DR3DDD cells at 37°C was 3777 AE 2745 pM, which is essentially in accordance with the results of a surface plasmon resonance-based study that analyzed TL1A binding to an immobilized DR3-Fc construct and reported a K D of 6450 AE 200 pM [1] . The K D for the TL1A-DR3 interaction was comparable to that for other death ligand/ death receptor pairs (e.g. 2000-3600 pM for CD95L-CD95, depending on cell type), but approximately two orders of magnitude higher than the K D of the TNF-TNFR1 interaction (19-47 pM) [30, 31] . Therefore, differences in the ligand-receptor affinity may contribute to the discrepancy in the LD 50 values for TNF and TL1A. Admittedly, cell-type dependent variations of the K D values of TNFSF ligands have been observed [30, 31] , and our measurements relied on a DR3 construct without a death domain. Moreover, the role of other variables such as the percentage of ligand-occupied TNFR1 or DR3 molecules necessary to trigger a cellular response, and the role of a membrane-bound DR3 splice variant lacking CRD4 [32] , remain to be determined.
Although ligand binding to death receptors triggers initial assembly of a signaling complex at the plasma membrane, some downstream signaling may depend on receptor internalization. For example, TNFR1 is capable of initiating pro-inflammatory signaling at the plasma membrane, but efficient cell death induction depends on receptor internalization [33] . Due to the high degree of similarity between TNFR1 and DR3, we hypothesized that TL1A also initiates DR3 internalization. Trimeric Flag-TNC-TL1A (Fig. 5A ,B,J,K) and oligomerized Flag-TNC-TL1A+M2 (Fig. 5D ,E) both efficiently triggered DR3 internalization, which was absent in DR3Dcyt-expressing cells (Fig. 5G,H) . Ligand-induced internalization of TNFR1 via clathrinmediated endocytosis critically depends on a cytoplasmic internalization motif located in the tail of the receptor [33] . Possibly, this also holds true for DR3, thereby explaining the predominant membrane-localized staining of HeLa DR3Dcyt cells (Fig. 5G,H) . Notably, TL1A also induced in HeLa DR3Dcyt cells a subtle change in the staining pattern from largely coalescent areas (Fig. 5G ) to distinct dots (Fig. 5H) , and a minor proportion of fluorescent spots translocated into the cytoplasm. The latter may indicate clathrinindependent mechanisms of receptor internalization.
Most functions of the TL1A-DR3 signaling axis in vivo are thus far thought to result from activation of non-apoptotic pathways. DR3 signaling, similar to TNFR1 signaling, occurs primarily through the TRADD-TRAF axis, with subsequent activation of NFjB and mitogen-activated protein kinase [3] . Physiological roles for non-apoptotic DR3 signaling in lymphocytes and myeloid cells and also outside the immune system have been demonstrated [4] . In this respect, the observed modest capability of DR3 to induce cell death reflects the predominant pro-inflammatory DR3 function in vivo. In fact, blockade of DR3 signaling, e.g. using neutralizing anti-TL1A antibodies, ameliorated the course of disease in several mouse models of immune pathologies [4] , and has received attention as a therapeutic approach in humans. Interestingly, in TNFR1 signaling, depletion of cytoplasmic cIAP1-TRAF2 complexes (e.g. via Fn14 or TNFR2 activation or treatment with SMAC mimetics) may shift the cellular response from inflammation to cell death [23, 24, 34] . For DR3 signaling, we showed that targeting cIAP1-TRAF2 complexes with SMAC mimetics boosts TL1A-induced cell death (Fig. 6) . Given the restricted DR3 expression on distinct cell types, which is often dependent on activation, e.g. in inflammatory processes, combination of SMAC mimetics with TL1A may constitute an approach to shut down disease-related pro-inflammatory DR3 signaling through targeted cell death induction. Taken together, we provide evidence that the soluble trimeric form of TL1A is fully capable of initiating signaling events via DR3, and is therefore fully sufficient to robustly activate DR3. Measurements of TL1A affinity to its receptor and demonstration of TL1A-induced DR3 internalization extend our understanding of this signaling axis, and may facilitate the development of novel approaches for therapeutic DR3 targeting.
Experimental procedures
Cells, antibodies and reagents . The TNFR1-specific mutant TNF(32W/86T) has been described previously [15] . Etanercept was obtained from Pfizer (Berlin, Germany). Anti-HA and Anti-Flag agarose was purchased from Sigma. Western blot analysis was performed as described previously [35] .
Plasmids, production and purification of recombinant proteins
The expression vectors encoding the TL1A constructs are derived from a variant of pCR3 (Life Technologies, Darmstadt, Germany) encoding an Ig signal peptide (provided by P. Schneider, Department of Biochemistry, University of Lausanne, Switzerland) followed by a Flag-TNC domain [36] . Flag-TNC-TL1A constructs were generated by inserting a TL1A amplicon encoding amino acids 92-251, including a stop codon, in-frame 5 0 to the Flag-TNC domain using standard cloning techniques. The Fc-Flag-TNC-TL1A construct was generated by in-frame insertion of Flag-TNC-TL1A into a pCR3 variant encoding the IgG1 Fc domain and a linker (kind gift from P. Schneider). Recombinant TL1A was produced in HEK293T cells by transient transfection with polyethylenimine. Briefly, 7.5 9 10 6 cells were seeded in 15 cm cell culture plates and transfected with a mixture of polyethylenimine and 25 lg DNA. The medium was replaced 6 h post-transfection. The supernatant was collected after 48-72 h, cleared by centrifugation (2000 g, 5 min 4°C), and purified by affinity chromatography using anti-Flag antibody-conjugated agarose beads (Sigma). After elution with Tris-buffered saline containing 100 lgÁmL À1 Flag peptide (Sigma), fractions were dialyzed against PBS and stored at À20°C for further analysis.
Co-immunoprecipitation
Co-immunoprecipitation of HA-Flag-TNC-TL1A was performed essentially as described previously for CD95L [35] . Briefly, 1 9 10 8 cells were stimulated with 200 ngÁmL
À1
HA-Flag-TNC-TL1A for the indicated times at 37°C, washed in ice-cold PBS, transferred into 1.5 mL lysis buffer (30 mM Tris/HCl, pH 7.5, 1% Triton X-100, 10% glycerol, 120 mM NaCl) supplemented with cOmplete TM protease inhibitor cocktail (Roche, Mannheim, Germany), and incubated for 20 min on ice. Lysates were cleared by centrifugation (2 9 20 min, 14 000 g), and DR3 complexes were precipitated using anti-HA antibodies coupled to agarose beads (Sigma, 40 lL of a 50% v/v slurry) at 4°C overnight. Lysates from non-stimulated cells supplemented with 50 ng of HA-Flag-TNC-TL1A before adding anti-HA antibody-coupled agarose beads served as a negative control. After washing in lysis buffer, agarose-bound proteins were eluted by incubation at 75°C for 10 min in 49 Laemmli sample buffer.
IL8 ELISA
For the IL8 ELISA, 7 9 10 4 TF-1 cells were stimulated in 0.2 mL medium with the indicated concentrations of soluble TNF ligands for 7 h in triplicate. Supernatant was collected, and IL8 was quantified by ELISA (BD Biosciences, Heidelberg, Germany).
Cell viability assay
TF-1 cells were seeded in 96-well plates (7 9 10 5 per well), treated with cycloheximide (2.5 lgÁmL À1 for 2 h), BV6
(10 lM for 4 h) or LCL161 (3 lM for 4 h), and subsequently stimulated with the indicated concentrations of the ligands in triplicate. Cell viability was determined 18 h after stimulation using MTT staining.
Caspase-3 activity assay
Caspase activity was determined using a caspase-3 activity kit (AAT Bioquest, Sunnyvale, CA, USA) according to the manufacturer's instructions. Light emission was quantified using a Victor3 multilabel reader (Perkin Elmer, Waltham, MA, USA).
Flow cytometry
DR3 surface expression of TF-1 cells (5 9 10 5 per group) was measured by staining with DR3-specific biotinylated antibody (R&D Systems), fluorescein isothiocyanate-conjugated donkey anti-goat antibody (Jackson ImmunoResearch, Baltimore, MD, USA) and avidin-coupled fluorescein isothiocyanate (R&D Systems). Biotinylated goat IgG (R&D Systems) served as a specificity control. TNFR1 surface expression was measured by staining with phycoerythrin-conjugated TNFR1-specific antibody (R&D Systems). Analyses were performed using a FACSCanto flow cytometer (BD Biosciences) according to standard procedures.
Binding studies
Bioluminescent binding studies using GpL-Flag-TNC-TL1A were essentially performed as described elsewhere [31] . DR3 expression was triggered by adding doxycycline (100 ngÁmL
À1
) for 18 h. Untreated samples served as controls to determine non-specific binding. Induced and untreated cells were incubated pairwise with increasing concentrations of GpL-Flag-TNC-TL1A for 1 h at 37°C to achieve equilibrium binding. Unbound ligand was removed by washing the plates 10 times for 5 s in ice-cold PBS. Next, cells were harvested using a rubber policeman, resuspended in 50 lL RMPI-1640 medium (0.5% v/v fetal bovine serum) and transferred to black 96-well plates. GpL activity was quantified by measuring luminescence using a Gaussia luciferase assay kit (New England Biolabs, Frankfurt am Main, Germany) in a luminometer (AnthosLabtec Instruments, Krefeld, Germany). Specific binding was defined as the difference between the total binding values in samples after doxycycline-triggered DR3 expression and the corresponding non-specific binding values in DR3-negative samples (without doxycycline). The maximum of specifically bound GpL activity (B max ) and the dissociation constant (K D ) were calculated using GRAPHPAD PRISM5 software (GraphPad software, La Jolla, CA, USA) (non-linear regression analysis, one site specific binding model).
Microscopy
For microscopy, 2. After three washing steps with PBS, nuclei were counter-stained with Hoechst 33342 (dilution 1:10 000, incubation for 10 min at room temperature). Cover slips were again washed three times using PBS, mounted on microscope slides, and analyzed using a Keyence BZ-9000 fluorescence microscope (Keyence, Osaka, Japan).
